Palivizumab and RSV prevention.
Carnegie
C
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D001990:Bronchiolitis, Viral / Q000628:therapy*; D017277:Drug Approval; D006801:Humans; D007167:Immunotherapy; D007223:Infant; D000069455:Palivizumab; D012107:Research Design; D018357:Respiratory Syncytial Virus Infections / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab